Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Natural history of prostate cancer.

Estebanez J, Teyrouz A, Gutierrez MA, Linazasoro I, Belloso J, Cano C, Peralta JM, Sanz JP.

Arch Esp Urol. 2014 Jun;67(5):383-7. Review. English, Spanish.

PMID:
24914836
2.

Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.

Leibovici D, Spiess PE, Agarwal PK, Tu SM, Pettaway CA, Hitzhusen K, Millikan RE, Pisters LL.

Cancer. 2007 Jan 15;109(2):198-204.

3.
4.

Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.

Aizer AA, Chen MH, Hattangadi J, D'Amico AV.

BJU Int. 2014 Jan;113(1):43-50. doi: 10.1111/j.1464-410X.2012.11789.x. Epub 2013 Mar 8.

5.

Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas.

Stege R, Grande M, Carlström K, Tribukait B, Pousette A.

Clin Cancer Res. 2000 Jan;6(1):160-5.

6.

Bladder neck invasion is an independent predictor of prostate-specific antigen recurrence.

Poulos CK, Koch MO, Eble JN, Daggy JK, Cheng L.

Cancer. 2004 Oct 1;101(7):1563-8.

7.

Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.

Zagars GK, Pollack A, von Eschenbach AC.

Int J Radiat Oncol Biol Phys. 1995 Aug 30;33(1):23-35.

PMID:
7543892
8.

Elevated stromal chondroitin sulfate glycosaminoglycan predicts progression in early-stage prostate cancer.

Ricciardelli C, Mayne K, Sykes PJ, Raymond WA, McCaul K, Marshall VR, Tilley WD, Skinner JM, Horsfall DJ.

Clin Cancer Res. 1997 Jun;3(6):983-92.

10.

Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.

Miyamoto S, Ito K, Miyakubo M, Suzuki R, Yamamoto T, Suzuki K, Suzuki K, Yamanaka H.

Prostate Cancer Prostatic Dis. 2012 Mar;15(1):75-86. doi: 10.1038/pcan.2011.47. Epub 2011 Oct 11.

PMID:
21986985
11.

Prostate cancer in Saskatchewan Canada, before and during the PSA era.

Skarsgard D, Tonita J.

Cancer Causes Control. 2000 Jan;11(1):79-88.

PMID:
10680732
12.

[Prostate-specific antigen in the diagnosis of organ-confined treatable prostate carcinoma].

Recker F.

Schweiz Med Wochenschr. 1996 Nov 2;126(44):1881-90. Review. German.

PMID:
8984601
13.

The role of prostate-specific antigen in the chemoprevention of prostate cancer.

Crawford ED, DeAntoni EP, Ross CA.

J Cell Biochem Suppl. 1996;25:149-55. Review.

PMID:
9027612
14.

Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.

Stamey TA, Ekman PE, Blankenstein MA, Cooper EH, Kontturi M, Lilja H, Oesterling JE, Stenman UH, Turkes A.

Scand J Urol Nephrol Suppl. 1994;162:73-87; discussion 115-27. Review.

PMID:
7529430
15.
16.

Prostate-specific antigen doubling time as a prognostic marker in prostate cancer.

Eastham JA.

Nat Clin Pract Urol. 2005 Oct;2(10):482-91. Review.

PMID:
16474622
17.
18.
19.

The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.

Sheridan T, Herawi M, Epstein JI, Illei PB.

Am J Surg Pathol. 2007 Sep;31(9):1351-5.

PMID:
17721190
20.

Predictive factors for progression in patients with clinical stage T1a prostate cancer in the PSA era.

Descazeaud A, Peyromaure M, Salin A, Amsellem-Ouazana D, Flam T, Viellefond A, Debré B, Zerbib M.

Eur Urol. 2008 Feb;53(2):355-61. Epub 2007 Jun 26.

PMID:
17611015

Supplemental Content

Support Center